Academic record 02
Oral presentations, posters, and invited talks.
Evaluating soluble mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) as a prognostic biomarker in metastatic renal cell carcinoma across three independent clinical trials.
Presenting an integrative analysis of circulating kidney injury molecule-1 (KIM-1) in patients with metastatic renal cell carcinoma.
Post-hoc analysis of JAVELIN Renal 101 evaluating circulating KIM-1 in metastatic RCC.
Presenting work evaluating host immune gene-expression signatures as predictors of response to ICI-based regimens in metastatic RCC.
Discussing the knowledge, precautionary behaviors, and psychological impact of the first COVID-19 wave on patients with cardiovascular disease in Lebanon.
Evaluating whether integrating KIM-1 and MAdCAM-1 into a composite risk score improves risk stratification beyond either biomarker alone and beyond IMDC criteria in metastatic renal carcinoma.
Evaluating whether real-world endpoints can serve as surrogate markers for overall survival in metastatic bladder cancer using a large real-world cohort.
Poster showing that prior irAEs during ICI therapy were associated with increased ADC toxicity across tumor types.
Poster detailing integrative clinical, genomic, and transcriptomic profiling of circulating KIM-1 in metastatic RCC.
Evaluation of circulating kidney injury molecule-1 (KIM-1) as a biomarker in metastatic RCC based on a post-hoc analysis of JAVELIN Renal 101.
Analysis of ERBB2 amplification patterns across sex, race, and multiple cancer types.
Poster on dual AXL and c-Met inhibition as a strategy to overcome therapeutic resistance in RCC.
Evaluation of ERBB2 mutations and their association with molecular phenotypes in urothelial carcinoma.
Invited talk at the Society for Immunotherapy of Cancer (SITC) Leveraging Biomarkers to Accelerate IO Drug Development Workshop, focused on practical implementation of immunotherapy biomarkers in genitourinary cancers.